Copyright © Inderes 2011 - present. All rights reserved.

ExpreS2ion Biotech Holding

15.66 SEK

-0.76 %

Less than 1K followers

EXPRS2

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.76 %
-7.67 %
-1.51 %
-14.52 %
-37.23 %
-41.57 %
-96.21 %
-98.52 %
-89.94 %

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

Read more
Market cap
55.28M SEK
Turnover
187.04K SEK
Revenue
3.01M
EBIT %
-2,249.17 %
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Michael Friis
Philip Coombes
Philip Coombes, Michael Friis
Show more
Latest research

Latest analysis report

Released: 14.01.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.2
2026

Annual report '25

19.5
2026

Interim report Q1'26

27.5
2026

General meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
ExpreS2ion Biotechnologies – Presentation of the 2025 Full-Year Report and Q&A
Webcast

ExpreS2ion Biotechnologies – Presentation of the 2025 Full-Year Report and Q&A

ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company’s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&A session.

ExpreS2ion Biotech Holding
ExpreS2ion Biotech (One-pager): Early Phase I clinical validation of ES2B-C001 de-risks near term development
Research by
Philip Coombes, Michael Friis

ExpreS2ion Biotech (One-pager): Early Phase I clinical validation of ES2B-C001 de-risks near term development

We have published an updated one-pager on ExpreS2ion Biotech following early immunogenicity data and dose escalation clearance in the Phase I ES2B-C001 breast cancer vaccine, which begins to de-risk near-term development, alongside the completed TO 11 warrant programme. The note also reflects the malaria licensing agreement with Serum Institute of India, which provides platform validation and limited non-dilutive funding, while ES2B-C001 remains the core value driver.

ExpreS2ion Biotech Holding
ExpreS2ion: Clearance to advance ES2B-C001 – supportive early signals, but still preliminary
Analyst Comment by
Michael Friis

ExpreS2ion: Clearance to advance ES2B-C001 – supportive early signals, but still preliminary

ExpreS2ion today reported updated immunogenicity data from the first three patients treated with its HER2-targeted breast cancer vaccine candidate ES2B-C001, alongside confirmation that the independent Data Safety Monitoring Board (DSMB) has reviewed safety data and recommended progression to the next dose cohort in the ongoing Phase I trial.

ExpreS2ion Biotech Holding
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.